February 26, 2024
GLP-1s are drugs proven to treat diabetes. But with high costs, increased use for other purposes and clinical uncertainty, GLP-1s are not without controversy. This brief underscores the history of these medications and makes policy recommendations to ensure patients are receiving the right drugs at the right time.
New from ACHP:
- ACHP Statement on Budget Reconciliation Bill
- ACHP Recommendations on Prescription Drug Machine-Readable File Requirement in Coverage Final Rule
- ACHP Opposes Senate Reconciliation Bill That Threatens Coverage for Millions
- ACHP Recommendations to Strengthen CMS Drug Price Negotiation Guidance for 2028
- GLP-1s Are Not A Silver Bullet
- Local Health Plans Meet Community Needs with Affordable, Accessible Vaccines
